Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

KIDS vs AXGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AXGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

AXGN Overall Winner 6-Pillar Tally: KIDS 1 – 5 AXGN Matrix Metrics: KIDS 3 – 7 AXGN

As of Nov 19, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas AXGN carries 35.3/100 (SELL) at $56.35 (79.7x Forward P/E, -5.2% operating margin).

  • Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. AXGN 35.3/100 SELL), AXGN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. -8.2% operating margin) and revenue trajectory (+26.2% vs. +18.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KIDS vs AXGN
KIDS NASDAQ
OrthoPediatrics Corp. Common Stock
Surgical & Medical Instruments & Apparatus
$32.51
+2.72% 1D
Market Cap $850.2M
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 0.81β · 108% Vol
Unified Composite Score
45.1 / 100 HOLD
Tech 28.0 Fund 40.0 Flow 50.0 Mom 46.3
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (12.1% over 20 days), RSI 64
RSI-14: 64.2 · SMA20: $30.90 · SMA50: $25.86
AXGN NASDAQ Head-to-Head Winner
Axogen, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$56.35
-1.05% 1D
Market Cap $3.4B
TTM Revenue $267M
Forward P/E 79.7x
Beta / 30D Vol 1.28β · 121% Vol
Unified Composite Score
35.3 / 100 SELL
Tech 50.0 Fund 28.0 Flow 62.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 68
RSI-14: 68.4 · SMA20: $50.34 · SMA50: $44.07

6-Pillar Scorecard Institutional Category Breakdown (KIDS 1 – 5 AXGN)

Columns: Metric · KIDS · AXGN
1. Valuation Multiples AXGN
Forward P/E N/M 79.7x
Trailing P/E N/M 125.0x
PEG Ratio N/M N/M
EV / Revenue 3.2x 11.6x
2. Growth & Scale AXGN
Revenue Growth (YoY) +18.6% +26.2%
Earnings Growth (YoY) +0.0% +300.0%
TTM Revenue (USD) $264M $267M
Market Cap $850.2M $3.4B
3. Profitability & Quality AXGN
Gross Margin 73.8% 74.2%
Operating Margin -8.2% -5.2%
Net Profit Margin -12.8% -12.0%
Return on Equity (ROE) -9.8% -10.3%
4. Balance Sheet & Cash Flow AXGN
Cash Generation (TTM) $1.1M EBITDA $20M
Cash Flow Margin 0.4% EBITDA Mgn 7.5%
Net Cash / Leverage $12.99 Book/Sh · -9.8% ROE $309M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AXGN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 145.1% (100th %ile) 67.0% (15th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat KIDS
OpEx & R&D Intensity 82.0% of Rev ($217M) 79.4% of Rev ($212M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KIDS (3) vs AXGN (7)
Institutional Metric KIDS AXGN Criterion Row Edge
Market Capitalization
Scale
$850.2M $3.4B Larger Scale AXGN
Trailing P/E Ratio
Valuation
N/M 125.0x Lower Multiple AXGN
Forward P/E Ratio
Valuation
N/M 79.7x Lower Multiple AXGN
Revenue Growth (YoY)
Growth
+18.6% +26.2% Higher Growth AXGN
Operating Margin (TTM)
Profitability
-8.2% -5.2% Higher Margin AXGN
Net Profit Margin
Profitability
-12.8% -12.0% Higher Margin AXGN
Return on Equity (ROE)
Capital Efficiency
-9.8% -10.3% Higher ROE KIDS
52-Week Range Position
Momentum
90% ($14–$35) 91% ($23–$60) Stronger Trend AXGN
Beta / 30D Volatility
Risk Regime
0.81β · 108% Vol 1.28β · 121% Vol Lower Realized Risk KIDS
Unified Institutional Score
Composite Signal
45.1 / 100 (HOLD) 35.3 / 100 (SELL) Higher Composite KIDS
Trailing 12M Revenue (USD)
Operating Scale
$264M $267M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
73.8% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 11.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.1M EBITDA ($12.99 Book/Sh · -9.8% ROE) $20M ($309M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AXGN +18.1 pp
KIDS: +36.37% · AXGN: +54.47%
3M Horizon KIDS +14.93 pp
KIDS: +26.74% · AXGN: +11.81%
6M Horizon KIDS +39.99 pp
KIDS: +76.4% · AXGN: +36.41%
1Y Horizon AXGN +35.85 pp
KIDS: +98.84% · AXGN: +134.69%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KIDS vs AXGN. Trailing 12-month operating profitability (KIDS -8.2% vs AXGN -5.2%) and valuation multiples (KIDS N/M vs AXGN 79.7x Forward P/E) are benchmarked directly in Pillar 4 below.

KIDS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$264M
Gross Margin73.8%
Op. Margin-8.2%
ROE / Fwd P/E-9.8% · N/M
AXGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$267M
Gross Margin74.2%
Op. Margin-5.2%
ROE / Fwd P/E-10.3% · 79.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KIDS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 145.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KIDS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AXGN SURGE
6d in phase · OBV NEUTRAL
Current IV 67.0%
IV Percentile 15th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KIDS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $850.2M market capitalization and -8.2% operating margin.
OpEx & R&D Reinvestment 82.0% of Rev ($217M)
90D Engineering Disclosures 0 Published
AXGN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.4B market capitalization and -5.2% operating margin.
OpEx & R&D Reinvestment 79.4% of Rev ($212M)
90D Engineering Disclosures 0 Published

Investor FAQ KIDS vs AXGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over OrthoPediatrics Corp. (KIDS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). KIDS carries a Unified Composite Score of 45.1/100 (HOLD) at $32.51 (N/M Forward P/E, -8.2% operating margin), whereas AXGN carries 35.3/100 (SELL) at $56.35 (79.7x Forward P/E, -5.2% operating margin). Composite vs. Pillar Nuance: While KIDS currently prints a higher short-term Unified Composite Score (45.1/100 HOLD vs. AXGN 35.3/100 SELL), AXGN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. -8.2% operating margin) and revenue trajectory (+26.2% vs. +18.6% YoY).

AXGN leads the Growth & Scale pillar: KIDS posts +18.6% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (73.8% gross margin, -8.2% operating margin), compared with AXGN at +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin). On trailing 12-month operating scale, KIDS generates $264M in USD-normalized revenue versus $267M for AXGN. In operating R&D and SG&A reinvestment, KIDS deploys 82.0% of Rev ($217M) (0 90-day corporate R&D disclosures) versus 79.4% of Rev ($212M) (0 disclosures) for AXGN.

AXGN screens cheaper on headline valuation multiples. KIDS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.2x EV/Revenue (0.4% EBITDA margin), whereas AXGN trades at 79.7x Forward P/E, 125.0x Trailing P/E, N/M PEG, and 11.6x EV/Revenue (7.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KIDS (-9.8% ROE) versus AXGN (-10.3% ROE) capital efficiency.

In options market volatility and institutional positioning, KIDS carries 145.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.81β · 108% Vol realized risk). By comparison, AXGN carries 67.0% implied volatility (15th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.28β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.